Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development
Former Generate Biomedicines, Amgen and Novartis senior leader Mike Nohaile joins Prellis as CEO SAN FRANCISCO–(BUSINESS WIRE)–Prellis Biologics, Inc (Prellis Bio), a biotherapeutics company, today appointed Michael Nohaile, PhD as its new CEO and announced it has raised a $35 million Series C funding round, co-led by Celesta Capital and Avidity Partners with participation from … [Read more…]
